About half of the patients suffering from heart failure present with sleep-disordered breathing. In most cases obstructive and central breathing disturbances (including CheyneStokes respiration [CSR]) coexist. CSR is defined by a waxing and waning pattern of the tidal volume. While its pathophysiology has not been elucidated completely, increased ventilatory sensitivity for CO 2 and therefore an imbalance of the respiratory drive and effort, a chronic hyperventilatory state, and changes of the apnoeic threshold are considered to play a relevant role. However, CSR in heart failure impairs survival and quality of life of the patients and is therefore a major challenge of respiratory sleep medicine. If CSR persists despite optimal medical and interventional therapy of the underlying cardiac disorder, oxygen supply, continuous positive airway pressure (CPAP), and bilevel pressure are often trialled. However, there is insufficient evidence to recommend oxygen or bilevel treatment. CPAP has proven to improve left ventricular function. In addition, retrospective analyses suggested a reduction of mortality under CPAP in heart failure patients with CSR. However, these findings could not be reproduced in the prospective controlled CanPAP trial. More recently, adaptive servoventilation (ASV) has been introduced for treatment of CSR or coexisting sleep-related breathing disorders. ASV devices aim at counterbalancing the ventilatory overshoot and undershoot by applying variable pressure support with higher tidal volume (TV) during hypoventilation and reduced TV during hyperventilation. ASV has proven to be superior to CPAP but the long-term efficacy and the influences on cardiac parameters and survival are still under investigation.
Introduction
Sleep-related breathing disorders are common in patients with heart failure. Javaheri and colleagues prospectively studied patients with stable heart failure and found a proportion of 51% with sleep-related breathing disorders; 40% of the disturbances were central and 11% obstructive. Both obstructive and central types of sleep apnoea result in sleep disruption and arterial oxyhaemoglobin desaturation [Javaheri et al. 1998 ]. Left ventricular systolic dysfunction, male gender, advanced age, and daytime hypocapnia have been identified as risk factors or markers for central sleep apnoea [Sin et al. 1999; Javaheri et al. 1995] . In addition to cardiac disorders, cerebrovascular diseases such as stroke predispose to the development of CheyneStokes respiration (CSR) [Nopmaneejumruslers et al. 2005; Lanfranchi et al. 2003; Sin et al. 1999; Solin et al. 1999; Bixler et al. 1998; Tkacova et al. 1997b ]. Bonnin-Vilaplana and colleagues found CSR in 20.6% of patients suffering from acute lacunar strokes [Bonnin-Vilaplana et al. 2009 ]. Patients with sleep apnoea have a high prevalence of atrial fibrillation and ventricular arrhythmias [Lanfranchi et al. 2003; Javaheri et al. 1998 Javaheri et al. , 1995 .
Most studies focusing on prognosis of central disturbances in patients with cardiovascular disorders show reduced survival rates in untreated central sleep apnoea (CSA)/CSR patients [Brack et al. 2007; Javaheri et al. 2007; Corra et al. 2006; Roebuck et al. 2004; Sin et al. 2000; Lanfranchi et al. 1999; Andreas et al. 1996; Hanly et al. 1993 ]. However, medical treatment of heart failure has substantially improved in recent years. Therefore, the question arose whether these advances might have influenced the prevalence and prognosis of CSR. Hagenah and colleagues followed 57 heart failure patients for 5 years and found no substantial change in the proportion and the survival of CSR. Cardiac resynchronization therapy significantly improved patient outcome [Hagenah et al. 2010] .
Patients with underlying cardiac diseases present with a huge variety of breathing disorders, including the obstructive sleep apnoea syndrome (OSAS), CSA and CSR [Iber et al. 2007; American Academy of Sleep Medicine, 2005 ]. The recurrent diminishment or cessation of the airflow in OSAS is accompanied with thoracic and abdominal motions proving the ongoing breathing drive and effort. In contrast, CSR is characterized by recurrent apnoeas and/or hypopnoeas alternating with prolonged hyperpnoeas in a waxing and waning pattern of the effort and tidal volume [American Academy of Sleep Medicine, 2005] . The cycle length averages 6090 seconds in CSR while it is shorter in other forms of CSA [Hall et al. 1996 ]. Ventilatory impulses generated by the brain stem are lacking in central apnoeas while CSR is characterized by an alternating pattern of ventilatory overshoot and undershoot. This results in periodic breathing. The term CSR should be used for the coincidence of periodic breathing and heart failure ( Figure 1 ). Similar to OSAS the central sleep apnoea syndromes can be, but do not necessarily have to be, associated with daytime sleepiness, frequent nocturnal awakenings or insomnia. Sleepiness is less common in CSR as compared with OSAS. Fatigue and reduced exercise capacity are often leading symptoms of heart failure and are not thought to be related to a sleep-related breathing disorder. Occasionally, patients with CSA and heart failure report paroxysmal nocturnal dyspnea, nocturnal angina and recurrent arrhythmias. As arousals, hypoxaemia and breathing effort can increase the sympatheticoadrenal activity, CSR impairs heart function Naughton et al. 1995a] .
Pathophysiology of CheyneStokes respiration
The pathophysiology of CSR has not yet been completely elucidated. However, several crucial aspects can be mentioned:
. Appearance of central disturbances predominantly during non-rapid eye movement (non-REM) sleep. . Overshoot and undershoot of the ventilation. . Relation of the actual PCO 2 and the apnoea threshold.
Ventilatory drive and minute ventilation are reduced during sleep physiologically. However, an increase of the PaCO 2 stimulates ventilation, whereas ventilation is reduced during hypocapnia. This influence of the CO 2 level is dampened during REM sleep because muscles activity is diminished and the threshold to arousal from sleep is increased [Bradley and Phillipson, 1992; Phillipson, 1978] . Ventilation is controlled in a regulatory circuit containing the lungs and thorax, the chemoreceptors and the brain stem.
Wellmann and colleagues suggested the term loop gain which represents the ratio of ventilatory response to any breathing disturbances [Wellman et al. 2003] . A high loop gain results in a ventilatory overshoot with hyperventilation and hypocapnia leading to apnoeas. The loop gain is increased in non-REM sleep as compared with REM [Xie et al. 1994 ].
The apnoea threshold is defined by the level of the PaCO 2 below which breathing ceases. If it is elevated or the actual PaCO 2 decreases below the threshold, an apnoea emerges. The pattern of periodic breathing appears if the prevailing PaCO 2 and the apnoea threshold lie near to each other because in this constellation small variations of the ventilation lead to oscillations of the PaCO 2 above and below the apnoea threshold [Xie et al. 2002] .
Hyperventilation and the associated reduced level of the PaCO 2 narrow the distance between the PaCO 2 and the apnoea threshold. A chronic hyperventilatory state is a typical finding in CSR patients due to the stimulation of pulmonary irritant receptors and a higher reactivity of the chemoreceptors. Pulmonary congestion in heart failure irritates intrapulmonary receptors. Solin and colleagues showed a significant correlation between the pulmonary capillary wedge pressure (PCWP), a marker of pulmonary congestion, and the apnoeahypopnoea index (AHI). Moreover, the improvement of the PCWP is associated with a distinct improvement of the AHI [Lorenzi-Filho et al. 2002; Solin et al. 1999; Yu et al. 1998; Hanly et al. 1993] . Xie and colleagues found that the ventilatory response to increasing CO 2 levels was significantly elevated in patients with CSA [Xie et al. 2002] . These findings were confirmed by Solin and colleagues who showed an increased response to hypercapnia in heart failure with periodic breathing. Hyperreactivity of the chemoreceptors does not characterize heart failure in general, but only heart failure associated with central breathing disturbances [Solin et al. 2000 ].
The clinical relevance of arousals differs substantially between obstructive sleep apnoea and CSR. Arousals restore the waking state of nonchemical control of breathing, lower the CO 2 set point and increase the ventilatory reactivity. Therefore, ventilation is rapidly elevated in the sleepwake transition. Moreover, arousals increase the activity of the pharyngeal muscles which is crucial in the termination of obstructive apnoeas. In contrast, in CSR arousals increase the ventilatory overshoot resulting in a vicious circle of hyperventilation, central apnoea and arousal. Therefore, arousals propagate periodicity and induce breathing disturbances rather than terminating instability [Xie et al. 1994; Naughton et al. 1993; Bradley and Phillipson, 1992] .
Treatment of CheyneStokes respiration
There is a general consensus in the medical community that the therapy of an underlying disease has priority. If this does not suffice additional attempts have to be made to control symptoms. Therefore, the first step in the therapy of CSR is the optimization of the underlying cardiac or neurologic diseases. This includes the surgical or medical improvement of cerebral blood flow, the treatment of brain tumours or the pharmacological or interventional therapy of cardiac diseases.
Only a few nonrandomized studies have investigated the effects of cardiac drugs in heart failure patients with breathing disturbances [Tamura et al. 2009; Solin et al. 2000; Walsh et al. 1995 ]. Tamura and colleagues found that carvedilol significantly improved the left ventricular function, reduced the level of brain natriuretic peptide and the number of central apnoeas [Tamura et al. 2009 ]. Similarly, Walsh and colleagues showed a significant improvement of respiratory disturbances, sleep profile and subjective sleep quality under captopril in heart failure patients [Walsh et al. 1995] .
In addition to pharmacological approaches, cardiac resynchronization therapy (CRT) has been proven to effectively improve severe left ventricular systolic dysfunction. Kara and colleagues investigated whether CRT might influence respiratory disturbances in heart failure patients. They found a significant improvement of central disturbances under active stimulation with atrial synchronized biventricular pacemakers in 12 patients with heart failure and left ventricular ejection fraction of 28±2.8% [Kara et al. 2008 ].
Vermes and colleagues recently presented the course of a patient with heart failure treated with a biventricular assist device followed by heart transplantation. They described a resolution of central and obstructive apnoeas with the mechanical assist device but recurrence of the obstructive apnoeas after heart transplantation [Vermes et al. 2009 ].
Administration of oxygen, carbon dioxide or drugs
The ventilatory overshoot resulting from an increased loop gain is a characteristic phenomenon of CSR. Oxygen, carbon dioxide and sedative drugs may interfere with the regulatory circuit and therefore reduce the hyperreactivity of the system to CO 2 . They have an influence on the gas tensions in the blood, downregulate chemoreceptors or have an impact on the brainstem activity ( Figure 2 ).
The application of oxygen is broadly used in the therapy of CSR. It increases the oxygen supply of the left ventricle and additionally may reduce the reflex activation of the peripheral chemoreceptors. However, results of clinical trials on the efficacy are conflicting. Sasayama and colleagues compared breathing of room air and oxygen in 65 patients with moderate heart failure. They found that oxygen supply normalized the desaturation index and improved left ventricular function. However, the reduction of the AHI was limited to 50% [Sasayama et al. 2006 ]. In contrast, Gold and colleagues found that supplemental oxygen may increase frequency of obstructive apnoeas in patients with mixed disease [Gold et al. 1985] . In addition, oxygen supplementation failed to improve sleep parameters, clinical symptoms and cognitive failure in CSA patients [Krachman et al. 1999; Staniforth et al. 1998 ]. Moreover, the application of high inspired oxygen concentration was accompanied by an impairment of the left ventricular end-diastolic pressure (LVEDP) and the relaxation time [Mak and Newton, 2001] . While Staniforth's group found a general reduction of sympathetic activity, Andreas and colleagues only showed an improvement of muscular sympathetic nerve activity during voluntary apnoeas but not during resting ventilation in healthy subjects [Andreas et al. 2003; Staniforth et al. 1998 ].
The level of the PCO 2 is of crucial importance in the pathophysiology of CSR. Hypocapnia leads to hypoventilation and apnoeas. Therefore, the elevation of the actual PCO 2 could break through the periodicity of ventilation. Several studies using external application of CO 2 or enlargement of the dead space have proven this hypothesis and shown that CO 2 normalizes ventilation in CSR [Lorenzi-Filho et al. 1999; Andreas et al. 1998; Xie et al. 1997 ]. Andreas and colleagues applied a mixture of oxygen and carbon dioxide to a small group of heart failure patients. The transcutaneous CO 2 level increased and the portion of time with CSR reduced significantly [Andreas et al. 1998 ]. However, this improvement was associated with a significant increase of sympathetic activity. Most recently, Mebrate and colleagues studied mathematically the influence of phasic CO 2 application in different dosages and at different time points of the breathing cycle and found a short period in which CO 2 administration highly effectively stabilized respiration with minimal increase of the PCO 2 [Mebrate et al. 2009 ]. Despite these exciting theoretical considerations the application of CO 2 outside of clinical trials cannot be recommended at the moment because overdosage of CO 2 can be life threatening.
There have been attempts to influence the respiratory control system in the brain stem pharmacologically. Javaheri studied the mild diuretic and respiratory stimulant acetazolamide in a small-sized and short-term but randomized, double-blind, crossover, placebo-controlled trial. He found a significant decrease of the PaCO 2 as compared with placebo which indicated an increase of ventilation. The total AHI and the central apnoea index (CAI) decreased significantly. However, the remaining CAI was 23±21/h under verum so that acetazolamide cannot be regarded as clinically effective [Javaheri, 2006] . Javaheri and colleagues applied theophylline and placebo to 15 male patients with stable heart failure in a double-blind, crossover study for 5 days. They found significant improvements but not normalization of respiratory parameters under theophylline [Javaheri et al. 1996 ]. While the PaCO 2 did not change significantly under verum in this trial, in contrast, Andreas and colleagues showed that the application of theophylline was associated with a reduction of the transcutaneous PCO 2 [Andreas et al. 2004; Javaheri et al. 1996] .
It has been shown that arousals destabilize ventilation and therefore might aggravate respiratory disturbances in CSR [Younes, 2004] . Thus, Younes applied pentobarbital in a placebo-controlled animal trial to suppress arousals and stabilize ventilation. They found increases of genioglossus activity and an elevation of the apnoeic threshold, which is a precondition to stabilizing breathing. However, the author found serious blood gas alterations with prolonged hypoxia. Data on the suppression of arousals in human beings are not yet available [Younes, 2004] .
Continuous positive airway pressure and bilevel ventilation
Continuous positive airway pressure (CPAP) can have an influence on the regulatory circuit by improving the gas exchange in the lungs. It optimizes the matching of ventilation and perfusion, reduces the alveolo-arterial oxygen difference, and elevates oxygen supply to the heart. Moreover, CPAP decreases the cardiac preload and the left-ventricular transmural pressure, reduces the ventilatory effort and the work of breathing which diminishes the oxygen consumption of the respiratory muscles and the oxygen demand of the heart [Mansfield et al. 2004; Kaneko et al. 2003; Kaye et al. 2001; Javaheri, 2000; Sin et al. 2000; Tkacova et al. 1997a; Naughton et al. 1995b Naughton et al. , 1995c Davies et al. 1993; Buckle et al. 1992; Malone et al. 1991] .
Based on these pathophysiological findings CPAP has been the standard of treatment of CSR, but it reduces the numbers of apnoeas and hypopnoeas per hour (the AHI) by only 50% in both short-and long-term studies Teschler et al. 2001] . CPAP improves left ventricular ejection fraction and survival in heart failure patients who suffer from CSR [Sin et al. 2000; Naughton et al. 1995a ]. Sin and colleagues showed that the patients' odds ratio of dying was 2.5 if they suffered from CSR compared with normal nocturnal breathing [Sin et al. 2000 ]. Naughton and colleagues found increased oesophageal pressure swings and left-ventricular transmural pressure in heart failure as compared with healthy persons indicating increased work of breathing and left ventricular afterload, respectively. Both parameters significantly improved in the patients but did not change in healthy subjects. Moreover, cardiac index worsened under CPAP in the healthy group but remained stable in heart failure patients under CPAP [Naughton et al. 1995a ].
Despite these promising preliminary results, the prospective, randomized, controlled CanPAP trial failed to prove superiority of CPAP as compared with medical treatment in terms of survival . Two hundred and fiftyeight heart failure patients with an ejection fraction of 24.5±7.7% and CSA were randomized to receive CPAP or standard medical therapy for a mean of 2 years. Although, cardiac function, respiratory disturbances, sympatheticoadrenal activity and exercise performance significantly improved with CPAP, the study missed the primary outcome parameter ]. However, Arzt and colleagues reanalysed the CanPAP data and showed a survival benefit in those patients whose breathing disturbances were sufficiently reduced as compared with those without improvement of respiratory disturbances. Therefore, optimal suppression of respiratory disturbances is essential in CSR patients [Arzt et al. 2007 ].
Often bilevel positive pressure therapy is applied to patients with CSR not responsive to CPAP. Nevertheless, there are very limited data on the treatment of CSR with bilevel. Kö hnlein and colleagues compared the efficacy of bilevel in the spontaneous/timed mode (ST) with CPAP in a crossover study for 2 weeks each with a 2-week wash-out period in between in patients with CSA and chronic congestive cardiac failure. Both modes improved respiratory disturbances, subjective and objective parameters of sleep quality and also left ventricular function with no significant difference between them [Kö hnlein et al. 2002] . However, the body of evidence on bilevel therapy is very limited so that it cannot generally be suggested for the treatment of CSR.
Adaptive servoventilation
Most recently new devices have been developed to optimally address the pathophysiology and the clinical presentation of CSR. The adaptive servoventilation (ASV) counterbalances the shift between hyperpnoea and hypoventilation by applying variable pressure support and thus overcomes the ventilatory overshoot. During hypoventilation the difference between inspiratory and expiratory pressure, that means the pressure support and the tidal volume, increases while it is reduced during hyperventilation. In addition, ASV devices provide an expiratory positive airway pressure to eliminate obstructive apnoeas and hypopnoeas and also apply mandatory breaths to treat central apnoeas. Three algorithms are available at the moment which are distributed under the terms 'adaptive servoventilation', 'auto servoventilation' and 'anticyclic modulated ventilation'. However, the term 'adaptive servoventilation' is frequently used to describe the principle in general. The devices differ in the target parameters of the regulation, the backup frequency and the applicable pressure levels. Most recently, an algorithm has been released which combines ASV with automatic CPAP and pressure relief. Thus, it varies not only the pressure support but also the expiratory pressure to overcome upper airway obstruction automatically [Randerath et al. 2009a ].
After optimizing medical therapy we generally perform an individual trial with CPAP for two reasons: first, if CPAP sufficiently suppresses the respiratory disturbances ASV treatment is unnecessary; second, if CSR is incompletely resolved the CPAP level which eliminates obstructive disturbances serves as the expiratory pressure under ASV. Owing to the limited data on bilevel therapy in CSR and the similarity between CPAP and bilevel we do not recommend the use of bilevel but switch immediately to ASV if CPAP works insufficiently.
Case series and CPAP-controlled studies have been published focusing on the short-and medium-term efficacy, the quality of life and the heart function under ASV. Teschler and colleagues compared oxygen, CPAP, bilevel and ASV for one night each in a group of 14 patients [Teschler et al. 2001] . CPAP reduced the CAI by half. Although bilevel showed a better improvement of the mean CAI the individual results varied widely. In contrast, ASV normalized the CAI in almost all patients. Peperell and colleagues applied effective or subtherapeutical ASV for 1 month in a randomized, controlled, double-blind study. They included 30 CSA patients with chronic heart failure (left ventricular ejection fraction of 3336%) and mainly CSR/CSA. Effective ASV was superior in improving respiratory disturbances, daytime performance, cardiovascular and sympathetic markers [Pepperell et al. 2003 ]. Philippe and colleagues assigned 25 patients with CSA/CSR and stable HF (New York Heart Association [NYHA] class IIIV) to receive ASV or CPAP for 6 months. ASV proved to be superior to CPAP in terms of respiratory disturbances, heart function, quality of life, and compliance. However, there was no significant improvement of daytime sleepiness in either group. This might be due to the fact that the scores in the Epworth Sleepiness Scale were low at baseline giving only limited room for improvement [Philippe et al. 2006 ]. Morgenthaler and colleagues compared ASV and noninvasive bilevel ventilation in patients with CSA/CSR, complex sleep apnoea and mixed sleep apnoea. Both options sufficiently improved respiratory disturbances with ASV being superior compared with bilevel ventilation [Morgenthaler et al. 2007 ].
The efficacy of the treatment principle was also proved with different ASV devices. Arzt and colleagues studied 14 chronic heart failure patients after being insufficiently treated with CPAP or bilevel for a mean of more than 6 months. Once again, CPAP or bilevel significantly reduced the AHI by half compared with baseline while ASV normalized all respiratory parameters [Arzt et al. 2008] .
While most of the previous studies included patients with almost pure CSA/CSR, we focused on patients with coexisting obstructive sleep apnoea and CSR/CSA. This group seems to be more common in clinical practice as compared with pure CSR/CSA. We performed a prospective observational study on the efficacy of ASV in 10 male consecutive patients with coexisting OSAS and CSA/CSR with and without heart failure over 8 weeks. ASV proved to effectively suppress all types of respiratory disturbances and to improve sleep quality as measured by sleep stages and arousals. The results did not differ between patients with and without cardiovascular diseases [Randerath et al. 2008 ]. Kasai and colleagues confirmed these results in 31 heart failure patients who were treated for 3 months with CPAP or ASV [Kasai et al. 2010] . Preliminary data from a longterm CPAP-controlled trial in HF patients with coexisting obstructive sleep apnoea and CSA show a significant better improvement of the total and central AHI with ASV as compared with CPAP [Randerath et al. 2009b ].
In a similar group of patients the algorithm of 'anticyclic modulating ventilation' which combines ASV and automatic CPAP was tested in a 2-week pilot study. Seven of 12 patients suffered from arterial hypertension, coronary heart disease and mitral regurgitation, none of congestive heart failure. The device highly significantly reduced all phenotypes of respiratory disturbances to normal values [Randerath et al. 2009a ].
In addition to these convincing findings on the use of ASV in CSR we observed two problems in individual patients which rarely impaired the efficacy of ASV: mask leakages and closed central apnoeas. Pusalavidyasagar and colleagues described a higher prevalence of interface problems in patients with complex sleep apnoea [Pusalavidyasagar et al. 2006 ]. Active or passive closure of the upper airways ('diving reflex') can be supposed if an increase of the pressure support does not normalize CSR [Badr et al. 1995] . These phenomena should be primarily considered in the case of treatment failure with ASV [Randerath et al. 2008] .
In conclusion, the number of patients suffering from CSR or coexisting OSAS and CSR is rapidly increasing due to the aging of western societies, the increasing figures of cardiovascular comorbidities, the improvement of treatment options and the higher awareness of the problem in the medical community. Based on the clinical findings, ASV has proven to be highly effective in improving CSR. The method is superior to other positive pressure approaches, such as CPAP, bilevel or noninvasive ventilation. Therefore, ASV might become the new standard of treatment for CSR although data on the long-term results on efficacy and outcome are still to be expected. Nevertheless, a CPAP trial can be recommended as a first step of treatment of CSR because it suffices in about half of the patients and reduces mortality in the subgroup of CPAP responders. and complex sleep apnea syndromes. Sleep 30: 468475. Naughton, M., Benard, D., Tam, A., Rutherford, R. and Bradley, T.D. (1993) Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 148: 330338.
